Updated results from the OlympiA Phase III trial revealed that AstraZeneca and MSD’s Lynparza (olaparib) continues to show significant, clinically meaningful improvements in overall survival (OS), invasive disease-free survival (IDFS),…
Pfizer and Alliance Foundation Trials, LLC (AFT) recently unveiled findings from the Phase 3 PATINA trial, highlighting the potential of IBRANCE (palbociclib) in improving outcomes for patients with hormone receptor-positive…
Cyrus Biotechnology, Inc. has announced new data demonstrating the potent activity of its engineered IgG-degrading enzyme, CYR241, in a rabbit redosing model. Importantly, the study revealed that CYR241 does not…
SonarMD, a leading platform for value-based care (VBC) focused on complex, chronic gastrointestinal conditions, has presented new clinical findings at the Advances in Inflammatory Bowel Diseases (AIBD) conference in Orlando,…
The global market for Antisense & RNAi therapeutics is poised for significant growth, with projections estimating its value at US$5.4 billion in 2024. This market is expected to expand at…
Menarini Group, Stemline Therapeutics, and MEDSIR have presented groundbreaking research on the ADELA clinical trial, which targets therapeutic resistance in advanced ER+/HER2- breast cancer. This research was shared at the…
Sirius Therapeutics has announced promising preliminary results from its Phase 1 first-in-human clinical trial of SRSD107, a next-generation siRNA therapeutic under development for the prevention and treatment of thromboembolic disorders.…
Celltrion has announced that Health Canada has approved Omlyclo™, the first and only biosimilar referencing Xolair® (omalizumab) in Canada. Omlyclo™ is now authorized for the treatment of adults and adolescents…
SK pharmteco, a global leader in contract development, manufacturing, and analytical testing services for the pharmaceutical and cell & gene therapy industries, has announced a groundbreaking brand unification initiative. This…
Crown Bioscience, a leading global contract research organization (CRO) based in the United States and a part of JSR Life Sciences and Japan’s JSR Corporation, has been awarded the prestigious…
City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S., presented groundbreaking findings at the ASH Annual Conference in San Diego from…
Agilent Technologies today announced the issuance of a Class C Companion Diagnostic (CDx) In Vitro Diagnostic Regulation (IVDR) certification for its PD-L1 IHC 28-8 pharmDx (Code SK005) assay. This diagnostic…